Guanadrel

Summary

Guanadrel (CHEMBL1037) is an approved small-molecule antihypertensive agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 213.28 Da · C10H19N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1037
Name	Guanadrel
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	38521
ChEBI	CHEBI:5555
Molecular formula	C10H19N3O2
Molecular weight	213.28
InChIKey	HPBNRIOWIXYZFK-UHFFFAOYSA-N

SMILES: C1CCC2(CC1)OCC(O2)CN=C(N)N

IUPAC name: 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine

ChEBI definition: A spiroketal resulting from the formal condensation of the keto group of cyclohexanone with the hydroxy groups of 1-(2,3-dihydroxypropyl)guanidine. A postganglionic adrenergic blocking agent formerly used (generally as the sulfate salt) for the management of hypertension, it has been largely superseded by other drugs less likely to cause orthostatic hypotension (dizzy spells on standing up or stretching).

Pharmacological roles (ChEBI): antihypertensive agent, adrenergic antagonist.

Also known as: Guanadrel, guanadrel, GUANADREL

Parent form; salt/anhydrous children: CHEMBL3184143

Patent coverage: 604 distinct patent families (2,441 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,431 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).